PF-04856884

BIOLOGICAL2 trials

Sponsors

Pfizer

Conditions

GlioblastomaMetastatic Renal Cell Carcinoma

Phase 2

A Trial Of PF-04856884 In Patients With Recurrent Glioblastoma

WithdrawnNCT01225510

PfizerGlioblastoma

Start: 2011-01-31End: 2013-01-31Updated: 2015-03-11

PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma

TerminatedNCT01441414

PfizerMetastatic Renal Cell Carcinoma

Start: 2011-11-21End: 2014-03-27Updated: 2019-01-08